OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED). OKYO plans to file the IND to treat DED in the third or fourth quarter of 2022, followed by the planned commencement of a Phase 2 trial in DED patients in the fourth quarter of 2022.
OKYO has also been evaluating OK-201, a bovine adrenal-medulla lipidated preclinical analogue candidate that is currently in developmental stage.
A Focus on Ocular Therapies
- Skipping Phase 1
- Designing Phase 2 effectively as a Phase 3 registration trial
|Asset||Indication||Pre-Clinical||IND-Enabling Studies||Phase 1||Phase 2||Phase 3|
*Not requiredAnticipated start date Q4/2022
OK-101 Anticipated IND Submission date Q3, 2022
* Ocular topical drug delivery
*OK-101 Anticipated IND Submission date Q3, 2022
Anticipated Phase 2 start date Q4, 2022